↓ Skip to main content

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news
2 news outlets
twitter
11 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
160 Dimensions

Readers on

mendeley
147 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
Published in
Journal for Immunotherapy of Cancer, June 2019
DOI 10.1186/s40425-019-0623-z
Pubmed ID
Authors

Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 147 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 147 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 13%
Researcher 18 12%
Student > Ph. D. Student 17 12%
Student > Doctoral Student 13 9%
Other 11 7%
Other 22 15%
Unknown 47 32%
Readers by discipline Count As %
Medicine and Dentistry 38 26%
Biochemistry, Genetics and Molecular Biology 23 16%
Immunology and Microbiology 10 7%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Agricultural and Biological Sciences 6 4%
Other 15 10%
Unknown 47 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2021.
All research outputs
#1,071,970
of 20,536,352 outputs
Outputs from Journal for Immunotherapy of Cancer
#233
of 2,470 outputs
Outputs of similar age
#24,652
of 285,707 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 20,536,352 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,470 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,707 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them